Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Molnar, S; Scharnagl, H; Delgado, GE; Krämer, BK; Laufs, U; März, W; Kleber, ME; Katzmann, JL.
Clinical and genetic diagnosis of familial hypercholesterolaemia in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health Study.
Eur Heart J Qual Care Clin Outcomes. 2024; 10(7):632-640
Doi: 10.1093/ehjqcco/qcad075
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Scharnagl Hubert
- Co-authors Med Uni Graz
- März Winfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- AIMS: To investigate the prevalence of familial hypercholesterolaemia (FH) and compare the performance of clinical criteria and genetic testing in patients undergoing coronary angiography. METHODS AND RESULTS: The prevalence of FH was determined with the Dutch Lipid Clinical Network (DLCN), US 'Make Early Diagnosis to Prevent Early Death' (US-MEDPED), Simon Broome (SB) criteria, the 'familial hypercholesterolaemia case ascertainment tool' (FAMCAT), and a clinical algorithm. Genetic screening was conducted with a custom array from Affymetrix (CARRENAL array) harbouring 944 FH mutations.The study cohort consisted of 3267 patients [78.6% with coronary artery disease (CAD)]. FH was diagnosed in 2.8%, 2.2%, 3.9%, and 7.9% using the DLCN, US-MEDPED, SB criteria, and the FAMCAT. The clinical algorithm identified the same patients as the SB criteria. Pathogenic FH mutations were found in 1.2% (1.2% in patients with CAD, 1.0% in patients without CAD). FH was more frequently diagnosed in younger patients. With genetic testing as reference, the clinical criteria achieved areas under the ROC curve [area under the curves (AUCs)] in the range of 0.56-0.68. Using only low-density lipoprotein cholesterol (LDL-C) corrected for statin intake, an AUC of 0.68 was achieved. CONCLUSION: FH is up to four-fold more prevalent in patients undergoing coronary angiography than in contemporary cohorts representing the general population. Different clinical criteria yield substantially different diagnosis rates, overestimating the prevalence of FH compared with genetic testing. LDL-C testing alone may be sufficient to raise the suspicion of FH, which then needs to be corroborated by genetic testing. LAY SUMMARY: In this study, we investigated the frequency of familial hypercholesterolaemia-a common genetic condition leading to markedly elevated low-density lipoprotein (LDL) cholesterol and increased risk of atherosclerosis-in 3267 patients undergoing coronary angiography according to commonly used diagnostic scoring systems and genetic testing.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Coronary Angiography - methods
- Female - administration & dosage
- Hyperlipoproteinemia Type II - genetics, epidemiology, complications, diagnosis
- Male - administration & dosage
- Middle Aged - administration & dosage
- Genetic Testing - methods
- Prevalence - administration & dosage
- Mutation - administration & dosage
- Coronary Artery Disease - genetics, diagnosis, epidemiology
- Aged - administration & dosage
- Germany - epidemiology
- Algorithms - administration & dosage
- Cholesterol, LDL - blood
- Adult - administration & dosage
- Find related publications in this database (Keywords)
- Familial hypercholesterolaemia
- Genetic
- Dutch Lipid Clinical Network
- US-MEDPED
- Simon Broome
- FAMCAT